Elaine Yu

402 total citations
34 papers, 314 citations indexed

About

Elaine Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Elaine Yu has authored 34 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 9 papers in Economics and Econometrics. Recurrent topics in Elaine Yu's work include Colorectal Cancer Treatments and Studies (9 papers), Economic and Financial Impacts of Cancer (9 papers) and Cancer Treatment and Pharmacology (7 papers). Elaine Yu is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Economic and Financial Impacts of Cancer (9 papers) and Cancer Treatment and Pharmacology (7 papers). Elaine Yu collaborates with scholars based in United States, United Kingdom and Greece. Elaine Yu's co-authors include Yeun Mi Yim, Arliene Ravelo, Charles S. Cleeland, Nancy A Dreyer, Musa Mayer, Yong Mun, Zhaohui Su, Jeff A. Sloan, Peter A. Kaufman and Vincent S. Staggs and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Health Psychology.

In The Last Decade

Elaine Yu

31 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elaine Yu United States	10	191	102	44	39	39	34	314
Livio Blasi Italy	11	189 1.0×	89 0.9×	23 0.5×	22 0.6×	45 1.2×	49	377
Rishi Sawhney United States	7	197 1.0×	75 0.7×	41 0.9×	19 0.5×	26 0.7×	15	328
Christopher Su United States	11	149 0.8×	114 1.1×	15 0.3×	44 1.1×	23 0.6×	30	297
Asim Jamal Shaikh Pakistan	13	139 0.7×	56 0.5×	16 0.4×	12 0.3×	42 1.1×	40	318
T. Yau China	12	303 1.6×	107 1.0×	48 1.1×	10 0.3×	21 0.5×	18	504
Caroleen Quach United States	8	188 1.0×	70 0.7×	16 0.4×	18 0.5×	19 0.5×	13	342
Victoria Huynh United States	8	89 0.5×	43 0.4×	13 0.3×	21 0.5×	27 0.7×	30	264
Oliver Higuera Spain	13	305 1.6×	135 1.3×	16 0.4×	15 0.4×	61 1.6×	40	480
Nesrine Mejri Tunisia	10	126 0.7×	38 0.4×	37 0.8×	31 0.8×	54 1.4×	51	317
Shicheng Weng United States	9	126 0.7×	80 0.8×	90 2.0×	11 0.3×	72 1.8×	18	370

Countries citing papers authored by Elaine Yu

Since Specialization

Citations

This map shows the geographic impact of Elaine Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine Yu more than expected).

Fields of papers citing papers by Elaine Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine Yu. The network helps show where Elaine Yu may publish in the future.

Co-authorship network of co-authors of Elaine Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine Yu. A scholar is included among the top collaborators of Elaine Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine Yu. Elaine Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vidal, Gregory A., Neha Jain, Aaron Fisher, et al.. (2024). Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncology Practice. 20(3). 370–377. 3 indexed citations

Hansen, Aaron R., Charlene Mantia, Andrew Weickhardt, et al.. (2024). 72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations. European Journal of Cancer. 211. 114599–114599.

Stricker, Thomas, Esprit Ma, Elaine Yu, et al.. (2024). Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes. The Oncologist. 29(6). 534–542. 4 indexed citations

Vidal, Gregory A., Neha Jain, Aaron J. Fisher, et al.. (2023). Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.. Journal of Clinical Oncology. 41(16_suppl). 6508–6508. 1 indexed citations

Liu, Raymond, Christine B. Weldon, Nancy P. Gordon, et al.. (2022). Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model: Assessment in a Large Health System and a Blueprint for Other Institutions. JCO Oncology Practice. 19(1). e125–e137. 6 indexed citations

Trosman, Julia R., Christine B. Weldon, Bruce D. Rapkin, et al.. (2021). Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non–Safety-Net Centers. JCO Oncology Practice. 17(8). e1202–e1214. 6 indexed citations

Vanderwalde, Ari M., Esprit Ma, Elaine Yu, et al.. (2021). NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).. Journal of Clinical Oncology. 39(28_suppl). 288–288. 3 indexed citations

Trosman, Julia R., Christine B. Weldon, Della Makower, et al.. (2020). 4R program results: What is the impact of 4R care delivery model on patient self-management and which patients benefited?. Journal of Clinical Oncology. 38(29_suppl). 139–139.

Necchi, Andrea, Guru Sonpavde, Salvatore Lo Vullo, et al.. (2016). Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). Annals of Oncology. 27. vi277–vi277. 1 indexed citations

10.

Bamias, Aristotelis, Kimon Tzannis, Michalis Liontos, et al.. (2016). Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis. Annals of Oncology. 27. vi278–vi278. 2 indexed citations

11.

Chen, Clara, Arliene Ravelo, Elaine Yu, Rahul Dhanda, & Ian D. Schnadig. (2015). Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices. Journal of Neuro-Oncology. 122(3). 595–605. 10 indexed citations

12.

Thomas, Nina, et al.. (2015). The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. Journal of Medical Economics. 19(5). 497–505. 27 indexed citations

13.

Cleeland, Charles S., Musa Mayer, Nancy A Dreyer, et al.. (2014). Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. The Breast. 23(6). 763–769. 53 indexed citations

14.

Byfield, Stacey DaCosta, et al.. (2013). Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents. Journal of Medical Economics. 16(8). 1071–1081. 6 indexed citations

15.

Cartwright, Thomas H., et al.. (2012). Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology. Clinical Colorectal Cancer. 11(4). 238–246. 28 indexed citations

16.

Shankaran, Veena, David Mummy, Lisel Koepl, et al.. (2012). Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(3). 204–213.e1. 10 indexed citations

17.

Dranitsaris, George, et al.. (2012). Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(2). 120–127. 5 indexed citations

18.

Yang, Hongbo, Andrew P. Yu, Eric Q. Wu, Yeun Mi Yim, & Elaine Yu. (2011). Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. Journal of Medical Economics. 14(5). 542–552. 8 indexed citations

19.

Walker, Mark S., et al.. (2011). Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health and Quality of Life Outcomes. 9(1). 46–46. 14 indexed citations

20.

Flack, John M., et al.. (1995). Panel I: Epidemiology of minority health.. Health Psychology. 14(7). 592–600. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact